Indiva Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Indiva has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings growing at 43.8% annually. Revenues have been growing at an average rate of 42.1% per year.
Belangrijke informatie
6.8%
Groei van de winst
19.6%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 23.1% |
| Inkomstengroei | 42.1% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -11.8% |
| Laatste winstupdate | 31 Mar 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Indiva Limited's (CVE:NDVA) Subdued P/S Might Signal An Opportunity
May 28
Indiva Limited (CVE:NDVA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Sep 29Is Indiva (CVE:NDVA) Using Debt In A Risky Way?
Sep 17Is Indiva (CVE:NDVA) A Risky Investment?
Apr 19Is Indiva (CVE:NDVA) Using Too Much Debt?
Feb 26Would Indiva (CVE:NDVA) Be Better Off With Less Debt?
Sep 04Would Indiva (CVE:NDVA) Be Better Off With Less Debt?
Nov 30Opbrengsten en kosten
Hoe Indiva geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 24 | 37 | -4 | 11 | 1 |
| 31 Dec 23 | 38 | -5 | 11 | 1 |
| 30 Sep 23 | 36 | -7 | 12 | 1 |
| 30 Jun 23 | 34 | -9 | 12 | 1 |
| 31 Mar 23 | 35 | -10 | 12 | 1 |
| 31 Dec 22 | 34 | -11 | 13 | 1 |
| 30 Sep 22 | 34 | -12 | 13 | 1 |
| 30 Jun 22 | 34 | -16 | 13 | 1 |
| 31 Mar 22 | 35 | -15 | 13 | 1 |
| 31 Dec 21 | 32 | -15 | 11 | 0 |
| 30 Sep 21 | 30 | -18 | 10 | 0 |
| 30 Jun 21 | 25 | -15 | 10 | 0 |
| 31 Mar 21 | 19 | -16 | 8 | 0 |
| 31 Dec 20 | 15 | -15 | 8 | 0 |
| 30 Sep 20 | 8 | -11 | 7 | 0 |
| 30 Jun 20 | 5 | -10 | 6 | 0 |
| 31 Mar 20 | 3 | -10 | 7 | 0 |
| 31 Dec 19 | 1 | -11 | 9 | 0 |
| 30 Sep 19 | 1 | -11 | 10 | 0 |
| 30 Jun 19 | 0 | -10 | 10 | 0 |
| 31 Mar 19 | 0 | -10 | 9 | 0 |
| 31 Dec 18 | 0 | -9 | 7 | 0 |
| 30 Sep 18 | 0 | -7 | 6 | 0 |
| 30 Jun 18 | 0 | -6 | 5 | 0 |
| 31 Mar 18 | 0 | -5 | 3 | 0 |
| 31 Dec 17 | 0 | -3 | 2 | 0 |
| 30 Sep 17 | 0 | -2 | 2 | 0 |
| 30 Jun 17 | 0 | -2 | 2 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Kwaliteitswinsten: NDVA.H is currently unprofitable.
Groeiende winstmarge: NDVA.H is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: NDVA.H is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Versnelling van de groei: Unable to compare NDVA.H's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: NDVA.H is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Rendement op eigen vermogen
Hoge ROE: NDVA.H's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.